{
    "clinical_study": {
        "@rank": "23342", 
        "arm_group": {
            "arm_group_label": "HBV vaccine", 
            "arm_group_type": "Experimental", 
            "description": "HBV vaccine (Engerix-B, recombinant hepatitis B surface antigen, 20\u00b5g/mL/vial, GlaxoSmithKline, Belgium)"
        }, 
        "brief_summary": {
            "textblock": "At present, children less than 15 y of age have been regarded as a key group for hepatitis B\n      immunization in China. However, there is not yet special immunization strategy for\n      population above 15 y of age. In this study, we investigated the seroprevalence of hepatitis\n      B and immune response to HB vaccine among Chinese college students to uncover the need on\n      universal mass vaccination or booster immunization only for students with HBV vaccination\n      history against hepatitis B in Chinese college students to inform decision making."
        }, 
        "brief_title": "Seroprevalence of Hepatitis B and Immune Response to Hepatitis B Vaccination in Chinese College Students", 
        "condition": [
            "Hepatitis B", 
            "Immune Response", 
            "Seroprevalence"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Hepatitis", 
                "Hepatitis A", 
                "Hepatitis B"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male and female freshmen in one college in Liuzhou city of Guangxi Zhuang Autonomous\n             Region\n\n        Exclusion Criteria for vaccination study:\n\n          -  acute illness\n\n          -  immunocompromised conditions\n\n          -  renal insufficiency\n\n          -  pregnancy\n\n          -  allergic history to HB vaccine or yeast\n\n          -  positive for any of HBsAg, anti-HBs or anti-HBc"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "30 Years", 
            "minimum_age": "16 Years"
        }, 
        "enrollment": {
            "#text": "2040", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "May 19, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01861613", 
            "org_study_id": "PRO-HBV-001"
        }, 
        "intervention": {
            "arm_group_label": "HBV vaccine", 
            "intervention_name": "HBV vaccine (Engerix-B, recombinant hepatitis B surface antigen, 20\u00b5g/mL/vial, GlaxoSmithKline, Belgium)", 
            "intervention_type": "Biological"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 23, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Nanning", 
                    "country": "China", 
                    "state": "Guangxi"
                }, 
                "name": "Guangxi Centers for Disease Control and Prevention"
            }
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "1", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "November 2011", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Anti-HBs immune response in participants negative for HB sAg, anti-HBs and anti-HBc", 
            "safety_issue": "No", 
            "time_frame": "Anti-HBs was assayed at Month 7"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01861613"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Peking University", 
            "investigator_full_name": "Hui Zhuang", 
            "investigator_title": "Professor", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "Seroprevalence for HBsAg, anti-HBs and anti-HBc in Chinese college students", 
                "safety_issue": "No", 
                "time_frame": "seroprevalence at baseline"
            }, 
            {
                "measure": "Anti-HBs immune response in participants negative for HBsAg, anti-HBs and anti-HBc", 
                "safety_issue": "No", 
                "time_frame": "Anti-HBs immune response  at Month 1"
            }, 
            {
                "measure": "Anti-HBs immune response in participants negative for HBsAg, anti-HBs and anti-HBc", 
                "safety_issue": "No", 
                "time_frame": "Anti-HBs immune response at Month 6"
            }, 
            {
                "measure": "Anti-HBs immune response in participants negative for HBsAg, anti-HBs and anti-HBc", 
                "safety_issue": "No", 
                "time_frame": "Anti-HBs immune response at Month 20"
            }
        ], 
        "source": "Peking University", 
        "sponsors": {
            "collaborator": {
                "agency": "Guangxi Center for Disease Control and Prevention", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Hui Zhuang", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "September 2009", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "May 2013"
    }
}